EEG frequency peaks and band amplitudes obtained from spectral analysis of epochs from four cortical areas during the maximal, stable effect after (1.0 mm) NT as compared with Ringer's 2-a
| Drug trials | ANCOVA | |||||||
|---|---|---|---|---|---|---|---|---|
| Ringer's | NT | Drug (F) | df | Area (F) | df | Drug × Area (F) | df | |
| High peak frequency (30–60 Hz) | Mean ± SEM | |||||||
| Avg | 36.1 ± 0.3 | 36.3 ± 0.2 | 0.7 | 1 | 1.2 | 3 | 0.6 | 3 |
| F | 36.2 ± 0.7 | 35.8 ± 0.6 | ||||||
| RS | 36.7 ± 0.5 | 36.4 ± 0.5 | ||||||
| P | 36.0 ± 0.6 | 36.7 ± 0.5 | ||||||
| O | 35.4 ± 0.9 | 35.9 ± 0.4 | ||||||
| Low peak frequency (1–10 Hz) | ||||||||
| Avg | 3.1 ± 0.1 | 4.1 ± 0.2 | 19.51 | 12-165 | 9.9 | 32-165 | 1.0 | 3 |
| F | 2.4 ± 0.1 | 3.0 ± 0.3 | ||||||
| RS | 3.2 ± 0.3 | 4.6 ± 0.3 | ||||||
| P | 3.4 ± 0.2 | 4.2 ± 0.3 | ||||||
| O | 3.3 ± 0.2 | 4.3 ± 0.3 | ||||||
| Band amplitude (AD) | ||||||||
| γ | ||||||||
| Avg | 139.2 ± 3.5 | 145.9 ± 3.8 | 4.129 | 1* | 325.0 | 32-165 | 0.6 | 3 |
| F | 74.3 ± 1.8 | 81.0 ± 3.1 | ||||||
| RS | 168.1 ± 3.6 | 170.7 ± 4.7 | ||||||
| P | 143.0 ± 4.5 | 157.6 ± 7.1 | ||||||
| O | 170.3 ± 4.8 | 174.4 ± 4.4 | ||||||
| δ | ||||||||
| Avg | 224.7 ± 8.8 | 123.3 ± 4.6 | 117.8 | 12-165 | 32.9 | 32-165 | 0.2 | 3 |
| F | 149.3 ± 11.6 | 82.8 ± 6.5 | ||||||
| RS | 281.1 ± 19.9 | 147.6 ± 9.7 | ||||||
| P | 205.4 ± 8.7 | 121.0 ± 8.7 | ||||||
| O | 263.0 ± 15.1 | 141.7 ± 8.2 | ||||||
| θ/δ | ||||||||
| Avg | 1.02 ± 0.03 | 1.27 ± 0.03 | 39.04 | 12-165 | 8.24 | 32-165 | 1.01 | 3 |
| F | 0.89 ± 0.04 | 1.03 ± 0.04 | ||||||
| RS | 1.06 ± 0.08 | 1.40 ± 0.08 | ||||||
| P | 1.06 ± 0.05 | 1.25 ± 0.05 | ||||||
| O | 1.08 ± 0.07 | 1.37 ± 0.08 | ||||||
| EMG | ||||||||
| Avg | 326.7 ± 23.0 | 385.0 ± 26.5 | 2.86 | 1 | ||||
↵F2-a Measures were taken from nine 4 sec epoch samples (at 1 min intervals from 4 to 12 min post-injection) from the four cortical areas (F, frontal; RS, retrosplenial; P, parietal; O, occipital) after Ringer's and NT in five rats. Statistics were performed on natural log (Ln) transformed values that were normally distributed. The average (Avg) values per drug condition and the individual values for each area per drug (mean and SEM) were calculated and reported from the raw values in Hz for frequency, in AD units for amplitude bands (100 μV ≅ 125 AD units) from EEG and EMG, or as the ratio of θ/δ. An analysis of covariance (ANCOVA) was performed with each EEG measure as the dependent variable, drug (2) and area (4) as the independent variables, and sample (9) and rat (5) as covariates (with dferror = 349). Significant main effects of drug (
↵* p < 0.05;
F2-160 p ≤ 0.01;
↵F2-165 p≤ 0.001) were not associated with any significant interactions of drug with area, thus not calling for post hoc tests per area.